323 related articles for article (PubMed ID: 30470303)
1. The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer.
Lancho O; Herranz D
Trends Cancer; 2018 Dec; 4(12):810-822. PubMed ID: 30470303
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells.
Wright JB; Brown SJ; Cole MD
Mol Cell Biol; 2010 Mar; 30(6):1411-20. PubMed ID: 20065031
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional suppression of HLA-B expression by c-Myc is mediated through the core promoter elements.
Peltenburg LT; Schrier PI
Immunogenetics; 1994; 40(1):54-61. PubMed ID: 8206526
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional Dysregulation of MYC Reveals Common Enhancer-Docking Mechanism.
Schuijers J; Manteiga JC; Weintraub AS; Day DS; Zamudio AV; Hnisz D; Lee TI; Young RA
Cell Rep; 2018 Apr; 23(2):349-360. PubMed ID: 29641996
[TBL] [Abstract][Full Text] [Related]
5. MYC activates transcriptional enhancers to drive cancer progression.
Nat Genet; 2024 Apr; 56(4):567-568. PubMed ID: 38480925
[No Abstract] [Full Text] [Related]
6. Divergent lncRNA MYMLR regulates MYC by eliciting DNA looping and promoter-enhancer interaction.
Kajino T; Shimamura T; Gong S; Yanagisawa K; Ida L; Nakatochi M; Griesing S; Shimada Y; Kano K; Suzuki M; Miyano S; Takahashi T
EMBO J; 2019 Sep; 38(17):e98441. PubMed ID: 31361039
[TBL] [Abstract][Full Text] [Related]
7. Keratinocyte transcriptional regulation of the human c-Myc promoter occurs via a novel Lef/Tcf binding element distinct from neoplastic cells.
Kolly C; Zakher A; Strauss C; Suter MM; Müller EJ
FEBS Lett; 2007 May; 581(10):1969-76. PubMed ID: 17466981
[TBL] [Abstract][Full Text] [Related]
8. DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC.
Xu J; Testa JR
J Biol Chem; 2009 Jul; 284(31):20593-601. PubMed ID: 19497851
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between oncogenic MYC and noncoding RNAs in cancer.
Tu R; Chen Z; Bao Q; Liu H; Qing G
Semin Cancer Biol; 2021 Oct; 75():62-71. PubMed ID: 33160022
[TBL] [Abstract][Full Text] [Related]
10. Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors.
Sur IK; Hallikas O; Vähärautio A; Yan J; Turunen M; Enge M; Taipale M; Karhu A; Aaltonen LA; Taipale J
Science; 2012 Dec; 338(6112):1360-3. PubMed ID: 23118011
[TBL] [Abstract][Full Text] [Related]
11. lncRNAs and MYC: An Intricate Relationship.
Iaccarino I
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28704924
[TBL] [Abstract][Full Text] [Related]
12. Selection for c-myc integration sites in polyclonal T-cell lymphomas.
Broussard DR; Mertz JA; Lozano M; Dudley JP
J Virol; 2002 Mar; 76(5):2087-99. PubMed ID: 11836386
[TBL] [Abstract][Full Text] [Related]
13. Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma.
Ryan RJ; Drier Y; Whitton H; Cotton MJ; Kaur J; Issner R; Gillespie S; Epstein CB; Nardi V; Sohani AR; Hochberg EP; Bernstein BE
Cancer Discov; 2015 Oct; 5(10):1058-71. PubMed ID: 26229090
[TBL] [Abstract][Full Text] [Related]
14. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus.
Xiang JF; Yin QF; Chen T; Zhang Y; Zhang XO; Wu Z; Zhang S; Wang HB; Ge J; Lu X; Yang L; Chen LL
Cell Res; 2014 May; 24(5):513-31. PubMed ID: 24662484
[TBL] [Abstract][Full Text] [Related]
15. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional amplification in tumor cells with elevated c-Myc.
Lin CY; Lovén J; Rahl PB; Paranal RM; Burge CB; Bradner JE; Lee TI; Young RA
Cell; 2012 Sep; 151(1):56-67. PubMed ID: 23021215
[TBL] [Abstract][Full Text] [Related]
17. MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch.
Jakobsen ST; Jensen RAM; Madsen MS; Ravnsborg T; Vaagenso CS; Siersbæk MS; Einarsson H; Andersson R; Jensen ON; Siersbæk R
Nat Genet; 2024 Apr; 56(4):663-674. PubMed ID: 38454021
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer.
Okabe A; Kaneda A
Cancer Sci; 2021 Jun; 112(6):2081-2088. PubMed ID: 33728716
[TBL] [Abstract][Full Text] [Related]
19. Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLo-5.
Kim T; Cui R; Jeon YJ; Lee JH; Lee JH; Sim H; Park JK; Fadda P; Tili E; Nakanishi H; Huh MI; Kim SH; Cho JH; Sung BH; Peng Y; Lee TJ; Luo Z; Sun HL; Wei H; Alder H; Oh JS; Shim KS; Ko SB; Croce CM
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4173-8. PubMed ID: 24594601
[TBL] [Abstract][Full Text] [Related]
20. Enhancers and MYC interplay in hematopoiesis.
Benetatos L; Benetatou A; Vartholomatos G
J Mol Med (Berl); 2020 Apr; 98(4):471-481. PubMed ID: 32144465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
